| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1460-9568.2006.04686.X |
| P698 | PubMed publication ID | 16623826 |
| P2093 | author name string | Mathieu Lesort | |
| Zhengkuan Mao | |||
| Yeun Su Choo | |||
| P2860 | cites work | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation | Q28246858 | ||
| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death | Q28287762 | ||
| Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro | Q28584697 | ||
| Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules | Q28590634 | ||
| Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms | Q28592026 | ||
| Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 | ||
| Huntington's disease: a synaptopathy? | Q33193898 | ||
| On the active site thiol of gamma-glutamylcysteine synthetase: relationships to catalysis, inhibition, and regulation | Q33566233 | ||
| Tissue transglutaminase: a possible role in neurodegenerative diseases | Q33881855 | ||
| Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. | Q33928419 | ||
| Transcriptional dysregulation in Huntington's disease | Q34001953 | ||
| Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates | Q34103541 | ||
| A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity | Q34169361 | ||
| Therapeutic opportunities in polyglutamine disease | Q34205521 | ||
| The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases | Q34440280 | ||
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease | Q34763178 | ||
| 3-Nitropropionate, the toxic substance of Indigofera , is a suicide inactivator of succinate dehydrogenase | Q35049569 | ||
| Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei | Q36395820 | ||
| Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. | Q37494492 | ||
| Inefficient degradation of truncated polyglutamine proteins by the proteasome | Q37592772 | ||
| Formation of γ-glutamyl-ε-lysine bridges between membrane proteins by a Ca2+-regulated enzyme in intact erythrocytes | Q39244222 | ||
| Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation | Q40540661 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| Huntington's disease, energy, and excitotoxicity | Q40580788 | ||
| Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway | Q40590116 | ||
| Mitochondria, free radicals, and neurodegeneration | Q41235574 | ||
| Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. | Q42438521 | ||
| N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease | Q43820046 | ||
| Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine | Q43873037 | ||
| 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease | Q44104440 | ||
| Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders | Q44233701 | ||
| Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice | Q44316963 | ||
| Minocycline is protective in a mouse model of Huntington's disease | Q44697618 | ||
| Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury | Q44922430 | ||
| Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation | Q45077697 | ||
| Mitochondrial defect in Huntington's disease caudate nucleus | Q45291734 | ||
| Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease | Q45293405 | ||
| Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease | Q45293583 | ||
| Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease | Q45297332 | ||
| Riluzole therapy in Huntington's disease (HD). | Q45297539 | ||
| Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. | Q45298533 | ||
| Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors | Q45299117 | ||
| Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease | Q45301207 | ||
| Impaired mitochondrial function results in increased tissue transglutaminase activity in situ | Q45301397 | ||
| Mechanism for the inhibition of transglutaminase 2 by cystamine | Q45302748 | ||
| Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model | Q45304699 | ||
| Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice | Q56772848 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| striatum | Q1319792 | ||
| P304 | page(s) | 1701-1710 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | European Journal of Neuroscience | Q5412733 |
| P1476 | title | Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells | |
| P478 | volume | 23 |
| Q37347572 | Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease |
| Q42408869 | Acrolein scavengers, cysteamine and N-benzylhydroxylamine, reduces the mouse liver damage after acetaminophen overdose |
| Q37078047 | Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia |
| Q92267922 | Cysteamine Protects Neurons from Mutant Huntingtin Toxicity |
| Q39785057 | Disease-toxicant screen reveals a neuroprotective interaction between Huntington's disease and manganese exposure |
| Q26822726 | Dysregulation of glutathione homeostasis in neurodegenerative diseases |
| Q89497605 | Exposure to 3-Nitropropionic Acid Mitochondrial Toxin Induces Tau Pathology in Tangle-Mouse Model and in Wild Type-Mice |
| Q51733341 | Impact of atypical mitochondrial cyclic-AMP level in nephropathic cystinosis. |
| Q34431244 | Inhibition of intracellular clusterin attenuates cell death in nephropathic cystinosis |
| Q34743269 | Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. |
| Q39031769 | Investigational agents for the management of Huntington's disease |
| Q39673821 | Matrix Metalloproteinases Are Modifiers of Huntingtin Proteolysis and Toxicity in Huntington's Disease |
| Q92479828 | Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure |
| Q45302980 | Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. |
| Q37776087 | Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease |
| Q64899737 | New directions in therapeutics for Huntington disease. |
| Q34392509 | Protection by glia-conditioned medium in a cell model of Huntington disease |
| Q37941268 | Role of manganese in neurodegenerative diseases |
| Q37441183 | The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? |
| Q92662205 | Therapeutic Advances for Huntington's Disease |
| Q92537416 | Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases |
| Q34487604 | Therapeutic advances in Huntington's Disease |
| Q28469280 | Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism |
Search more.